Recent Posts
- U.S. Supreme Court to hear vaccine case
- L.A. settles accident lawsuit for $7 million
- Judge ends 26 years of special education oversight for city schools
- Cranberry couple sues Target after trunk injures toddler
- Sacramento jury awards record $24.3 million to girl run over by dad’s truck
- Lawsuit pits Va. convicts against state parole board
- Goldman Sachs sued by big pension fund over pay
- Botox maker is not liable in girl’s death, O.C. jury says
- Suit alleging torture in Iraq can proceed
- Lawsuit takes aim at stun-gun manufacturer; Watsonville man says he suffered permanent injuries after being shocked in 2006
- Court awards bullied student $800,000
- Lawsuit Filed In Canton Hit-And-Run Case
- POLLS: Texting while driving caused death of North Naples bicyclist, Collier lawsuit contends
- Concerns Over ‘Metal on Metal’ Hip Implants
- Flavoring Ingredient Recalled; Risk of Illness Seen as Low
Archived Posts
- March 2010 (52)
- February 2010 (144)
- January 2010 (119)
- December 2009 (8)
- November 2009 (165)
- October 2009 (1)
- June 2009 (29)
- April 2009 (61)
- March 2009 (140)
- February 2009 (156)
- January 2009 (151)
- December 2008 (143)
- November 2008 (113)
- October 2008 (192)
- September 2008 (88)
- August 2008 (8)
- July 2008 (29)
Blogroll
Pages
Meta
Data From Studies of Pfizer Neurontin Drug May Have Been Skewed
November 13, 2009
Researchers say trials of Pfizer Inc.’s Neurontin epilepsy treatment for uses that were not yet approved may have been skewed to emphasize favorable results.
Comparisons of internal company documents with published data from 12 clinical trials found inconsistencies between data that made it into the medical journals and findings from the original trials, according to a report in tomorrow’s New England Journal of Medicine. Discrepancies included reports of positive results from trials that were initially found to be negative, and primary study goals reported as secondary study goals.
Pfizer paid $430 million in criminal fines and civil penalties in 2004 for urging doctors to prescribe Neurontin for off-label uses. The drugmaker said the new review isn’t credible and the company didn’t attempt to mislead the medical community.
Read Article: Bloomberg
Posted By: Arizona Phoenix Attorneys for Accidents on the Premises of Others
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL